Cover of MD Newsline Oncology Brief

MD Newsline Oncology Brief

MD Newsline Oncology Brief

By: MD Newsline
Listen for free

Season's Savings | 0.99 €/month for 3 months

5.99 €/month thereafter - terms apply. Cancel monthly.
Summary
Welcome to MD Newsline Oncology Brief, your go-to source for concise, expert-led updates in the ever-evolving field of oncology. Designed for busy healthcare professionals, this podcast delivers focused insights from leading oncologists, researchers, and clinical experts. Each episode highlights the latest breakthroughs in cancer care, including emerging therapies, clinical trial updates, and practical treatment strategies. From immunotherapy advancements to real-world patient care approaches, we break down complex topics into clear, actionable takeaways. Whether you're an oncologist, physician, or part of the broader medical community, Oncology Brief helps you stay current without the noise. Our mission is to provide relevant, timely knowledge that supports better decision-making and improved patient outcomes. Tune in for quick, impactful conversations shaping the future of cancer care.2026 Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • AI and Oncology: How Machine Learning Is Reshaping Cancer Care and Research
    17 Nov 2026

    In this episode of MD Newsline, Dr. Christina Curtis, Professor of Medicine and Genetics at Stanford University and a leading researcher in computational oncology, explores how artificial intelligence is reshaping cancer research and patient care. Dr. Curtis discusses the growing role of AI in precision oncology, including digital pathology, molecular profiling, treatment response prediction, and the emerging concept of digital twins. She also shares insights into how machine learning can help identify high-risk patients, improve clinical trial design, and advance earlier cancer detection and prevention.

    Episode Highlights:

    AI and Precision Oncology

    Dr. Curtis explains how artificial intelligence is enabling researchers and clinicians to better understand tumor biology by integrating genomic, molecular, imaging, and clinical data. These technologies are helping create more personalized approaches to cancer diagnosis and treatment.

    Understanding Treatment Response and Resistance

    Advanced AI models can analyze large datasets to identify why therapies succeed or fail. Dr. Curtis discusses how these insights may help researchers uncover mechanisms of treatment resistance and develop more effective combination therapies.

    The Promise of Digital Twins

    Dr. Curtis explores the emerging concept of digital or molecular twins—computational models that use patient and population-level data to simulate disease progression and treatment outcomes. While still in development, these models have the potential to support clinical decision-making and trial design.

    Building the Infrastructure for AI-Driven Medicine

    Successful AI implementation requires standardized, high-quality data. Dr. Curtis highlights the importance of interoperable health systems, privacy-preserving data-sharing frameworks, and approaches such as federated learning to improve collaboration across institutions.

    AI in Clinical Practice

    As AI tools become more sophisticated, oncologists may benefit from risk prediction models, treatment recommendations, and therapy sequencing platforms. Dr. Curtis emphasizes the importance of clinician education, transparency, and trust in the development of these technologies.

    Digital Pathology and AI Biomarkers

    Emerging AI-powered pathology tools can analyze standard histopathology images to predict molecular characteristics and recurrence risk. These innovations may help improve access to precision medicine, particularly in resource-limited settings.

    Predicting Long-Term Breast Cancer Risk

    Dr. Curtis discusses ongoing efforts to use machine learning to identify patients at persistent risk of relapse, particularly in hormone receptor-positive breast cancer. Earlier identification of resistance mechanisms could support more effective treatment planning.

    Earlier Detection and Cancer Interception

    One of the most exciting frontiers in oncology is identifying disease before it becomes invasive. Dr. Curtis explains how AI may help detect precancerous changes earlier, creating opportunities for prevention and intervention before cancer develops.

    Key Takeaway

    Dr. Curtis emphasizes that artificial intelligence has the potential to transform every stage of cancer care—from prevention and early detection to treatment selection and long-term monitoring. By combining biological insights with advanced computational tools, AI may help deliver more precise, personalized, and proactive cancer care for patients worldwide.

    Resources:

    Website: https://mdnewsline.com/

    Newsletter: https://mdnewsline.com/subscribe/

    Connect with Dr. Christina Curtis: Here

    Show more Show less
    23 min
  • Myelofibrosis: JAK Inhibitors, Drug Interactions, and Patient Care
    10 Nov 2026
    In this episode of MD Newsline, Dr. Valentina Lana, PharmD, discusses the evolving treatment landscape of myelofibrosis and the critical role pharmacists play in optimizing patient outcomes. Drawing on her experience in community pharmacy, long-term care, and oncology-related medication management, Dr. Lana explores the hallmark features of myelofibrosis, current JAK inhibitor therapies, supportive care strategies, and emerging approaches aimed at modifying disease progression. She highlights the importance of individualized treatment planning, careful management of adverse effects and drug interactions, and multidisciplinary collaboration among pharmacists, physicians, nurses, and patients. Dr. Lana also discusses barriers to treatment access, the role of stem cell transplantation, and the potential future impact of combination therapies and precision medicine in myelofibrosis care. Episode Highlights Understanding Myelofibrosis and Its Clinical Impact Dr. Lana explains how myelofibrosis develops when abnormal stem cell activity leads to bone marrow fibrosis, impairing blood cell production. She discusses the three hallmark manifestations of the disease: symptom burden, splenomegaly, and cytopenias. Common symptoms include fatigue, low-grade fevers, weight loss, bone pain, and early satiety due to spleen enlargement. Treatment Goals in Myelofibrosis The primary goals of therapy are improving quality of life, controlling symptoms, reducing spleen size, and managing complications such as anemia and thrombocytopenia. Dr. Lana emphasizes the importance of balancing disease control with minimizing treatment-related toxicity. Risk Stratification and Personalized Care Dr. Lana reviews the role of prognostic tools such as DIPSS and MIPSS in evaluating disease severity and guiding treatment decisions. These tools help clinicians determine when a more aggressive versus conservative therapeutic approach may be appropriate. Current JAK Inhibitor Therapies The discussion covers currently approved JAK inhibitors used in myelofibrosis, including ruxolitinib, fedratinib, pacritinib, and momelotinib. Dr. Lana explains how each agent may be selected based on factors such as symptom burden, platelet counts, anemia status, and prior treatment response. Managing Adverse Effects and Drug Interactions Patients receiving JAK inhibitors may experience gastrointestinal side effects, infections, cytopenias, and other complications. Dr. Lana discusses practical counseling strategies, monitoring recommendations, and the importance of managing CYP3A4-mediated drug interactions to ensure safe and effective therapy. Supportive Care and Symptom Management Beyond disease-directed treatment, supportive care plays a major role in patient well-being. Dr. Lana reviews the use of erythropoiesis-stimulating agents, androgens, symptom-directed medications, and mental health support to address the physical and emotional challenges associated with myelofibrosis. Stem Cell Transplantation and Emerging Combination Therapies Allogeneic stem cell transplantation remains the only potentially curative option for eligible patients. Dr. Lana discusses how pharmacists help manage JAK inhibitor therapy during transplant preparation. She also highlights promising combination strategies and investigational agents designed to improve outcomes and potentially modify disease progression. Access Challenges and the Pharmacist's Role Obtaining specialty therapies can be complicated by insurance requirements, prior authorizations, and cost barriers. Dr. Lana explains how pharmacists advocate for patients, coordinate with healthcare teams, and explore assistance programs to ensure timely access to treatment. The Future of Myelofibrosis Treatment Looking ahead, Dr. Lana is optimistic about advances in precision medicine, mutation-targeted therapies, and combination regimens that may move beyond symptom management toward true disease modification. These innovations have the potential to improve long-term outcomes while reducing treatment burden. Key Takeaway Dr. Lana emphasizes that successful myelofibrosis management requires a personalized, multidisciplinary approach focused on symptom control, quality of life, and proactive monitoring. As new targeted therapies and combination treatments emerge, pharmacists will continue to play a pivotal role in optimizing care, improving access, and helping patients navigate an increasingly complex treatment landscape. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Valentina Lana: Here
    Show more Show less
    20 min
  • From Early Detection to Survivorship: Navigating Breast Cancer Treatment in 2026
    3 Nov 2026
    In this episode of MD Newsline, Dr. Ryan K. Ryder, medical oncologist and breast cancer specialist at the University of Kansas Cancer Center, discusses the evolving landscape of breast cancer diagnosis, treatment, survivorship, and pregnancy-associated breast cancer. He shares practical insights into modern screening strategies, genomic testing, targeted therapies, immunotherapy, fertility preservation, and patient-centered treatment planning. Dr. Ryder highlights how advances in precision oncology are transforming care across all breast cancer subtypes, helping clinicians tailor treatments based on tumor biology, genomic assays, and individual patient circumstances. He also discusses the growing role of multidisciplinary care, clinical trials, survivorship planning, and emerging research that continues to reshape breast cancer management. Episode Highlights: Breast Cancer Screening and Early Detection Dr. Ryder emphasizes the importance of routine breast cancer screening, noting that mammography remains the gold standard for early detection. He discusses the challenges of identifying breast cancer in younger women and explains how breast density can impact screening effectiveness and the need for supplemental imaging. The Role of Ultrasound, MRI, and Risk-Based Screening Patients with dense breasts or elevated risk factors may benefit from additional imaging such as ultrasound or breast MRI. Dr. Ryder reviews how risk assessment tools and genetic risk factors help guide personalized screening approaches. Genomic Testing and Precision Medicine Genomic assays such as Oncotype DX and Breast Cancer Index play a growing role in treatment decision-making. Dr. Ryder explains how these tools help determine recurrence risk, guide chemotherapy recommendations, and inform decisions regarding extended endocrine therapy. Liquid Biopsies and Circulating Tumor DNA The conversation explores the emerging role of circulating tumor DNA (ctDNA) testing. While currently most useful in metastatic breast cancer, ongoing research may expand its future applications in earlier-stage disease and treatment monitoring. Neoadjuvant vs. Adjuvant Therapy Decisions Dr. Ryder discusses how tumor subtype, stage, and surgical considerations influence decisions about treatment before surgery (neoadjuvant) versus after surgery (adjuvant). He highlights the importance of multidisciplinary collaboration among medical oncologists, surgeons, and radiation oncologists. Advances in Targeted Therapy New targeted therapies continue to improve outcomes for breast cancer patients. Dr. Ryder reviews the expanding use of CDK4/6 inhibitors, PARP inhibitors, and antibody-drug conjugates across multiple breast cancer subtypes and stages. Immunotherapy for Triple-Negative Breast Cancer Immunotherapy has significantly changed the treatment landscape for triple-negative breast cancer. Dr. Ryder discusses the impact of the KEYNOTE-522 trial and how pembrolizumab is being incorporated into treatment strategies for eligible patients. Managing Metastatic Breast Cancer For patients with metastatic disease, treatment goals focus on balancing disease control, quality of life, and treatment-related side effects. Dr. Ryder emphasizes open communication, individualized care, and ongoing access to clinical trials and emerging therapies. Survivorship and Long-Term Monitoring Survivorship planning begins early in the treatment journey. Dr. Ryder discusses monitoring cardiovascular health, bone density, metabolic health, and other long-term considerations that help improve overall outcomes for breast cancer survivors. Pregnancy-Associated Breast Cancer The episode also explores the unique challenges of diagnosing and treating breast cancer during pregnancy and the postpartum period. Dr. Ryder reviews safe imaging options, multidisciplinary treatment planning, fertility preservation strategies, and considerations for future pregnancy. Looking Ahead: The Future of Breast Cancer Care With new clinical trial data emerging regularly, Dr. Ryder believes breast cancer treatment will continue evolving rapidly. Advances in targeted therapies, immunotherapy, precision medicine, and treatment de-escalation strategies are expected to further improve outcomes while minimizing treatment burden. Key Takeaway Dr. Ryder emphasizes that early detection, personalized treatment planning, multidisciplinary care, and patient engagement remain central to improving breast cancer outcomes. As precision oncology continues to advance, clinicians and patients have more tools than ever to tailor treatment decisions and optimize long-term quality of life. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
    Show more Show less
    31 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet